Abstract
Prostaglandin-H synthase exists in two isoforms, PGHS-1 and PGHS-2. PGHS-1 is present and is constitutively expressed in most cells and tissues, whereas PGHS-2 is mainly thought to mediate inflammation. Selective prostaglandin-H synthase-2 (or cyclooxygenase-2) inhibitors have been shown to be potent antiinflammatory agents with fewer side effects than currently marketed nonsteroidal antiinflammatory drugs (NSAIDs). This review addresses the main classes of the selective PGHS-2 inhibitors whose selectivity is documented by supporting PGHS-1 and PGHS-2 enzyme data. In addition, we also describe our experience in design, synthesis and pharmacological in vivo evaluation of new 1,2-benzodioxole derivatives as candidate of the selective PGHS-2 inhibitors, with special attention to molecular dynamics simulations of these derivatives attached to the active site of PGHS-2.
Keywords: nsaids, pghs-2 inhibitors, 3d-pharmacophore model, molecular dynamics, acety isalicylic acid, diclofenac, sulindac, indomethacin, piroxicam, selective pghs-2 inhibitors, 1,2-diarylcyclopentenes
Current Medicinal Chemistry
Title: Selective PGHS-2 Inhibitors: A Rational Approach for Treatment of theInflammation
Volume: 9 Issue: 8
Author(s): C. R. Rodrigues, M. P. Veloso, H. Verli, C. A.M. Fraga, A. L.P. Miranda and E. J. Barreiro
Affiliation:
Keywords: nsaids, pghs-2 inhibitors, 3d-pharmacophore model, molecular dynamics, acety isalicylic acid, diclofenac, sulindac, indomethacin, piroxicam, selective pghs-2 inhibitors, 1,2-diarylcyclopentenes
Abstract: Prostaglandin-H synthase exists in two isoforms, PGHS-1 and PGHS-2. PGHS-1 is present and is constitutively expressed in most cells and tissues, whereas PGHS-2 is mainly thought to mediate inflammation. Selective prostaglandin-H synthase-2 (or cyclooxygenase-2) inhibitors have been shown to be potent antiinflammatory agents with fewer side effects than currently marketed nonsteroidal antiinflammatory drugs (NSAIDs). This review addresses the main classes of the selective PGHS-2 inhibitors whose selectivity is documented by supporting PGHS-1 and PGHS-2 enzyme data. In addition, we also describe our experience in design, synthesis and pharmacological in vivo evaluation of new 1,2-benzodioxole derivatives as candidate of the selective PGHS-2 inhibitors, with special attention to molecular dynamics simulations of these derivatives attached to the active site of PGHS-2.
Export Options
About this article
Cite this article as:
Rodrigues R. C., Veloso P. M., Verli H., Fraga A.M. C., Miranda L.P. A. and Barreiro J. E., Selective PGHS-2 Inhibitors: A Rational Approach for Treatment of theInflammation, Current Medicinal Chemistry 2002; 9 (8) . https://dx.doi.org/10.2174/0929867024606786
DOI https://dx.doi.org/10.2174/0929867024606786 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Products from Mediterranean Diet: From Anti-Inflammatory Agents to Dietary Epigenetic Modulators
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Subject Index to Volume 9
Current Pharmaceutical Design Opioid Free Anaesthesia and Cancer
Current Pharmaceutical Design The Mechanism of Mucus Production in Bronchial Asthma
Current Medicinal Chemistry Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in Experimental Myocarditis
Current Pharmaceutical Design Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Evaluation of Oxidative Stress Biomarkers in Brain Metastatic and Non-Metastatic Lung Cancer Patients with Different Cell Types
Anti-Cancer Agents in Medicinal Chemistry Osteoarthritis - An Update
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents New Anticancer Drugs from Marine Cyanobacteria
Current Drug Targets Antimicrobial Peptides: Promising Compounds Against Pathogenic Microorganisms
Current Medicinal Chemistry Acknowledgements to Reviewers
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Vascular Dysfunction and Insulin Resistance in Aging
Current Vascular Pharmacology Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets The Treatment of Autoimmune Hepatitis
Current Clinical Pharmacology Recent Patents of DNA Methylation Biomarkers in Gastrointestinal Oncology
Recent Patents on DNA & Gene Sequences Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Genomics and Proteomics of Nucleoside Transporters
Current Pharmacogenomics A Novel Natural Polymers Based Nanoparticles Gel Formulation for the Treatment of Rheumatoid Arthritis: Optimization and <i>In-vivo</i> Evaluation
Drug Delivery Letters Analgesic Prodrugs for Combating their Side-Effects: Rational Approach
Current Drug Delivery Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain
Current Pharmaceutical Design